F-star Therapeutics, Inc : F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
F-star Therapeutics, Inc.: F-star Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 17, 2021 (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announces first quarter 2021 financial results and provides a corporate update.
Strengthens balance sheet with successful closing of
$65 million public offering of common stock and;
Received $9.2 million in net proceeds under its at-the-market equity offering program
LAG-3 and PD-(L)1 co-targeting validation with LAG-3 validated in late-stage clinical trial as third checkpoint inhibitor pathway
FS118
FS222 presentation at AACR on the importance of tuning both affinity and avidity for differentiation
F-star Therapeutics, Inc. Announces Pricing of $65 Million Public Offering of Common Stock
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 07, 2021 (GLOBE NEWSWIRE) F-star Therapeutics, Inc. (Nasdaq: FSTX) (the Company or F-star ), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced the pricing of its underwritten public offering of 9,285,715 shares of its common stock at a public offering price of $7.00 per share. All of the shares to be sold in the offering are being sold by F-star. In addition, F-star has granted to the underwriters a 30-day option to purchase up to 1,392,857 additional shares of common stock. The offering is expected to close on or about May 11, 2021, subject to the satisfaction of customary closing conditions. The proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by F-star, ar
F-star Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) F-star Therapeutics, Inc. (Nasdaq: FSTX) (the Company or F-star ), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that it has commenced an underwritten public offering of its common stock. F-star also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the aggregate number of shares of common stock offered in the public offering on the same terms and conditions. All of the shares of common stock in the offering are to be sold by F-star.
F-star Therapeutics, Inc.: Study Published in Nature Shows F-Star s STING Agonist SB 11285 Enhances Preclinical Efficacy of Radiation Therapy
SB 11285 is a Second Generation STING Agonist Delivered Intravenously
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 19, 2021. The study entitled STING enhances cell death through regulation of reactive oxygen species and DNA damage demonstrates that systemic administration of a STING agonist in combination with radiation in a preclinical model enhances local control in Head and Neck Squamous Cell Carcinoma (HNSCC) and suggests that STING expression in the tumor is required for maximal therapeutic benefit. The studies described in this paper demonstrate that systemic administration of SB 11285, a novel STING agonist, in combination with radiation, enhances the antitumor effects in animal models of HNSCC. Furthermore, STING expression in the tumor can be used as a predictive biomarker and a combination of radiation with SB 11285 dem